Background-Although peak oxygen consumption (peak VO 2 ), 6-minute walk distance (6MW), and natriuretic peptides (BNP and NT-proBNP) are predictors of mortality in heart failure (HF) patients, it is not known whether therapy-induced changes in these measures can predict therapeutic effect on mortality. The objective of this analysis is to quantitatively assess the relationship between therapeutic effects on commonly proposed short-term markers in HF trials and therapeutic effects on long-term outcome in patients with HF and left ventricular dysfunction. Methods and Results-We identified drug or device therapies for which there exists at least 1 randomized, controlled trial (RCT) assessing mortality over at least 6 months in at least 500 patients. For each of these therapies, we identified RCTs assessing the short-term changes in VO 2 , 6MW, BNP, and NT-proBNP (few of the mortality RCTs assessed the short-term changes in markers). For each intervention, we calculated the odds ratio for mortality (using random effect meta-analysis when necessary), as well as the trial level average drug-or device-induced change in the markers. We assessed the correlation between the odds ratio for death with the placebo-corrected change in the functional parameter or biomarker across the interventions. We identified mortality RCTs of 27 distinct therapies (nϭ73 267 patients) with a median follow-up of 19 months, that directed the search for RCTs of the effect of those interventions on the functional markers and biomarkers. There were 54 peak VO 2 trials (nϭ4646 patients), 34 6MW trials (nϭ6995 patients), 15 BNP trials (nϭ7233), and 6 NT-proBNP trials (nϭ1946) included in this analysis. There was no significant correlation between the average therapy-induced placebo-corrected change in peak VO 2 and the odds ratio for mortality (rϭ0.158, Pϭ0.26). Increased drug or device-induced average change in 6MW was correlated with increased odds ratio for mortality (rϭ0.373, Pϭ0.036). There was no significant correlation between the average therapy-induced, placebocorrected change in the natriuretic peptides and the odds ratio for mortality (BNP: rϭϪ0.065, Pϭ0.82, Pϭ0.15). There was no apparent relation between change in the functional parameter or biomarker and categorical effect on mortality. Conclusions-This analysis, limited to trial level data from different therapeutic eras, suggests that drug-or device-induced effects on peak VO 2 , 6MW, and natriuretic peptides found in short-term trials do not predict the corresponding average long-term therapeutic effects on mortality for patients with HF and left ventricular dysfunction. (Circ Heart Fail. 2011;4:578-588.) Key Words: biomarkers Ⅲ peak VO 2 Ⅲ 6-minute walk Ⅲ systolic heart failure Ⅲ meta analysis
R ecent years have seen significant development of drug and device therapies for heart failure (HF) with favorable impact on mortality. 1 So too, there are numerous examples of agents that have progressed to evaluation in phase 3 clinical trials only to yield neutral or negative effects on survival. [2] [3] [4] [5] [6] Designing trials to evaluate potential therapies efficiently, both with respect to time and resources, is a continuing challenge for the research community. In an effort to meet this challenge there is significant interest in identifying short-term markers of mortality. 7 Although no single short-term marker can reasonably be expected to wholly predict the effects of a drug or device on the clinical outcomes of patients with a disease process as complex as HF, it was recently shown that there is a significant correlation and a salient predictability signal between short-term trial level therapeutic effects on left ventricular (LV) remodeling and longer-term trial level therapeutic effects on mortality in patients with HF and LV dysfunction (LVD). 8 Further identification of other short-term signals that may be predictors of longer-term outcomes in HF patients could significantly expedite development of new therapies for HF.
Clinical Perspective on p 588
In addition to ventricular remodeling, 3 other commonly postulated short-term markers for HF outcomes are peak VO 2 , 6-minute walk distance (6MW), and natriuretic peptides. 7 A decreased value of peak VO 2 is a hallmark clinical feature of HF, and LVD is considered an objective measure of exercise capacity and reflects prognosis for patients with advanced HF. 9, 10, 11, 12 The 6MW, primarily used in cardiology research trials, is relatively easy to perform, well tolerated by patients, and has also been shown to correlate with exercise capacity and mortality. [13] [14] [15] Natriuretic peptides are proteins that relate to and reflect the pathophysiological disturbances that accompany the syndrome of clinical HF. 7 Plasma levels of brain natriuretic peptide (BNP) and the N-terminal precursor protein (NT-proBNP) have both been shown to correlate with prognosis for patients with HF and have thus been suggested as surrogate markers in clinical trials. 16, 17, 18 It is not known how well short-term intervention-induced changes in the measures of peak VO 2 , 6MW, BNP, and NT-proBNP correlate with longer-term therapeutic changes on mortality. In this study, we systematically evaluate the degree to which the average therapy-induced changes in these markers is associated with corresponding interventioninduced effects on mortality in larger phase 3 clinical trials in patients with HF and LVD.
Methods

Overall Strategy
An ideal evaluative strategy would involve large clinical trials that are appropriately powered to assess both changes in mortality and also changes in short-term markers in all patients. Unfortunately, few such trials exist because of the time and expense needed to conduct these trials. As an extension of previously presented work, 8 we updated a systematic review of HF trials of effects of therapies on mortality and then performed a series of systematic reviews to identify trials of the effect of interventions on the markers of interest (peak VO 2 , 6MW, and natriuretic peptides). Subsequently, we examined the relationship between trial-level changes in the measured short-term endpoints and effects on mortality with the same therapeutic intervention.
Search Strategy
PubMed was systematically searched for randomized controlled trials (RCTs) of intervention effects on mortality. The methods for this search have been previously reported 8 and the search was updated for this analysis. Briefly, the dataset was limited to randomized, controlled trials of interventions for the treatment of patients with HF with Ͼ6 months of follow-up and Ͼ500 patients. The trials from this search are referred to as mortality trials, and guided the searches for RCTs of intervention effects on the markers of interest.
PubMed was then systematically searched (covering January 1966 through September 2009) for RCTs with search terms related to each marker of interest. Separate searches were performed for peak VO 2 , 6MW, BNP, and NT-proBNP. The exact search terms are shown in the online-only Supplemental Materials.
Two reviewers examined the full-text articles of the potentially relevant abstracts for inclusion in the analysis and also examined citation lists from all papers to identify additional papers. We complemented these searches with input from field experts and perusal of the reference lists of review papers. When multiple articles reported on the same outcomes in overlapping sets of patients, we selected the one with the largest sample size, to avoid duplication of information. We required the measurement of a given marker in active drug and placebo groups over a period of at least 4 weeks. This duration was a prespecified cut-point meant to eliminate very short-term studies of acute effects. There was no minimum sample size for these short-term trials.
Data Extraction
Two investigators (B.S.W., J.L.K.) extracted data from the eligible trials, receiving input from an experienced methodologist when needed. For the mortality trials, number of patients, median follow-up time, class of HF, and odds ratio for long-term all-cause mortality was calculated. For the short-term marker trials, preconstructed data forms were used to extract publication information, the number of patients, duration of the trial, % ejection fraction (EF), mean age, sex, New York Heart Association (NYHA) class, HF etiology, and peak VO 2 , 6MW, BNP, or NT-proBNP data from placebo and intervention groups.
Calculation of Trial-Level (Mean) Effects on Mortality and Short-Term Outcomes
The general analytic approach and specific statistical analyses were those used in our recent publication on the relation between intervention effects on remodeling and effects on mortality. From each mortality trial we calculated the odds ratio for mortality. 8 When multiple studies existed, we derived summary effects using standard meta-analysis (Mantel-Haenszel method for 2 studies 19 and the DerSimonian and Laird random effects method for 3 or more studies). 20 We tested for heterogeneity with the Q statistic (considered significant for PϽ0.10) 21 and calculated its extent with I 2 . 22 I 2 expresses the proportion of between-study variability that is attributed to heterogeneity rather than chance, with values Ͼ50% indicating high heterogeneity. 23 From each short-term marker trial, we calculated the mean net difference of the change in the marker over time between intervention and placebo groups. The analyses considered effects from each of the short-term marker trials separately.
Data Analyses
As mentioned above, no RCT has assessed whether early changes in the markers can predict the effect of the therapies of interest on mortality in the same patients. We gain some insight on this question using summary data. Specifically for each therapy, we assessed if there is a correlation between the average short-term effects on the marker (obtained from the short-term marker trials) and the longterm effects on mortality (from the large mortality RCTs or their meta-analytic summaries). We created scatterplots of the summary odds ratio for mortality against the individual trial-level, placebocorrected change in the short-term marker. We calculated unweighted Spearman correlations between the trial-level intervention marker effects and the corresponding summary odds ratio for effect on mortality.
In a second set of analyses, we examined the relationship between trial level drug or device induced changes in the marker and the categorical (favorable, neutral, unfavorable) effect on mortality for a given intervention (ie, statistically significantly decreased, nonsignificant, or statistically significantly increased odds for mortality, respectively). An intervention was considered to have a favorable effect on mortality if the upper bound of the 95% confidence interval (CI) of the odds ratio (OR) was Ͻ1, a neutral effect on mortality if the 95% CI of the OR included 1, and an adverse mortality effect if the lower bound of the 95% CI of the OR was Ͼ1. We used independent sample Kruskal-Wallis (for 3 categories) or Mann-Whitney U (for 2 categories) tests to assess for differences across these categories.
All analyses were performed in Stata SE version 11 (Stata Corp, College Station, TX), Meta-Analyst (Tufts Evidence-based Practice Center, 2009) 24 and SPSS (Version 17.0. SPSS Inc, IBM Company, Chicago, IL). Unless otherwise stated, all probability values are 2-tailed and considered significant at the 0.05 level.
Results
Search Results
The search results are shown in Figure 1 .
Mortality Trials
We identified mortality RCTs of 27 distinct therapies with a median follow-up of 19 months that directed the search for RCTs of the effect of those therapies on the short-term outcomes (Table) . The detailed results of this search have been previously reported, 8 and the 3 interventions that are added to this updated mortality trials database, which were not previously reported, are exercise, 25 nonspecific immunomodulation, 26 and rosuvastatin 27 (online-only Supplement  Table 1 ).
Peak VO 2 Trials
We identified 5489 peak VO 2 trial citations with the initial PubMed search and 318 of these citations were reviewed in full text (Figure 1); 54 peak VO 2 trials (nϭ4646 patients) with a median follow-up of 24 weeks, representing 19 (70%) of the 27 previously identified mortality trial interventions were included in the analysis 28 -81 (Table) ; 22 of 56 (39%) of the peak VO 2 trial comparisons showed a significant placebocorrected change in peak VO 2 , whereas the remaining 34 (61%) showed no statistically significant drug or deviceinduced change in peak VO 2 over the course of the trial (online-only Supplement Table 2 ). Placebo-corrected change in peak VO 2 from each individual peak VO 2 trial was plotted against the mortality OR for the specific therapy ( Figure 2 ). The OR for mortality was not correlated with the drug/ device-induced placebo-corrected change in peak VO 2 (Spearman ϭ0.158, Pϭ0. 26) . Furthermore, of the 26 peak VO 2 evaluations that correspond to therapies with favorable effects on long-term mortality, only 9 of 26 (35%) show a significant increase in peak VO 2 (online-only Supplement Table 2 ). The average placebo corrected change in peak VO 2 was significantly different across interventions with a favor- Figure 1 . Search algorithms. The Mortality Search is previously reported 8 and was updated for this analysis. Abstracts screened represent the complete list of citations that was obtained from the systematic reviews. Italicized numbers refer to excluded citations. Full text review refers to the trials that were evaluated in detail for inclusion. Included randomized controlled trials (RCTs) represent the number of placebo-controlled RCTs that are included in the analyses. Total number of included trials may be different as some citations were obtained through sources other than PubMed. 6MW indicates 6-minute walk. Figure 3 ).
Table. Trial Level Study Populations: A Comparison of Study Populations Evaluated With the Different Outcomes
6MW Trials
We identified 4281 6MW trial citations with the initial Medline search and 222 of these citations were reviewed in full text (Figure 1 ). There were 34 distinct 6MW trials (nϭ6995 patients) with a median follow-up of 19 weeks included in the analysis 33, 37, 38, 40, 41, 43, 44, 47, 54, 106 (Table) ; 16 of 34 (47%) of the 6MW trial comparisons showed a significant placebo-corrected change in 6MW distance (online-only Supplement Table 3 ). Placebo-corrected change in 6MW distance from each individual 6MW trial was plotted against the mortality OR for the specific therapy ( Figure 4 ).
An increased odds ratio for mortality was statistically correlated with an increase in the drug/device-induced placebocorrected change in 6MW (Spearman ϭ0.373, Pϭ0.036).
For the 6MW trials that correspond to therapies with favorable effects on long-term mortality, only 45% (10 of 22) show a significant increase in 6MW distance (online-only Supplement Table 3 ). The average placebo corrected change in 6MW distance was statistically significantly different across interventions with favorable or neutral effect on mortality (Pϭ0.02 by Mann-Whitney test; Figure 5 ).
BNP Trials
We identified a total of 3107 trial citations with the initial natriuretic peptides Medline search, and 80 of these citations were reviewed in full text (Figure 1 ). We report these data separately for BNP and NT-proBNP because the molar ratio of these 2 biomarkers is highly variable and affected by numerous clinical factors including sex, renal function, and level of inflammation. 107, 108 There were 15 BNP trials (nϭ7233 patients) with a median follow-up of 24 weeks and 6 NT-proBNP trials (nϭ1946) with median follow-up of 12 weeks included in the analysis 44,45,67,82,93,109 -120 (Table) ; 11 of 15 (73%) of the BNP trial comparisons showed a significant placebo-corrected change in BNP, whereas 4 of 6 (67%) of the NT-proBNP trials report a significant change in this marker (Tables 4 and 5 ). Placebo-corrected change in BNP and NT-proBNP from each individual trial was plotted against the mortality OR for the specific therapy ( Figures 6  and 7) . The OR for mortality was not correlated with the drug/device-induced placebo-corrected change in BNP (Spearman ϭϪ0.0.65, Pϭ0.818) or NT-proBNP (Spearman ϭϪ0.67, Pϭ0.148). Of the 11 BNP evaluations that correspond to therapies with favorable effects on long-term mortality, 10 (91%) show a significant increase in BNP (onlineonly Supplement Table 4 ). The average placebo corrected change in BNP did not differ beyond chance across interventions with favorable or neutral effect on mortality (Pϭ0.36 by Figure 2 . Quantitative relationship between drug/device effects on peak oxygen consumption (VO 2 ) and mortality: Each data point represents a placebocorrected change in peak VO 2 from an individual trial plotted against the mortality odds ratio (OR) for the specific therapy. 8 Color-coded mortality effect is based on data from mortality trials listed in online-only Supplement Table 1 . Interventions were classified as favorable (yellow circles) if the upper limit of the 95% confidence interval (CI) of the OR for death from the mortality trials was Ͻ1, neutral (red circles) if the 95% CI crossed 1, and adverse (blue circles) if the lower limit of the 95% CI was Ͼ1. . Placebo-corrected change in peak VO 2 from peak VO 2 trials (y-axis) is plotted against effect on mortality (combined odds ratio) from mortality trials, represented as categorical outcomes favorable, neutral, or unfavorable (x-axis). Interventions were classified as favorable if the upper limit of the 95% confidence interval (CI) of the odds ratio for death from the mortality trials was Ͻ1, neutral if the 95% CI crossed 1, and unfavorable if the lower limit of the 95% CI was Ͼ1. Individual data points representing statistically significant (PϽ0.05) change in peak VO 2 are represented unfilled (white) markers. Individual data points representing nonsignificant changes in peak VO 2 are presented as filled markers. Figure 8 ). All of the NT-pro-BNP trials correspond to therapies that have a categorically favorable or neutral effect on mortality. Of these trials, 3 (67%) show a significant placebo-corrected change in NT-proBNP (onlineonly Supplement Table 5 ).
Mann-Whitney test;
Discussion
The prognostic significance of biomarkers such as BNP or NT-proBNP or functional parameters such as peak VO 2 or 6MW testing have led researchers to consider them as potential surrogates for longer-term outcomes in clinical research trials of therapies for HF. However, there have been no systematic evaluations of how well drug-or device-induced changes in these markers correlate with mortality. This evaluation is the first analysis of how well short-term intervention induced changes in these markers predict long-term therapy-induced changes in mortality. In contrast to recent data showing a salient predict-ability signal between short-term effects on LV remodeling parameters and longer-term effects on mortality, 8 the current data suggest that therapy-induced changes in peak VO 2 , 6MW, BNP, and NT pro-BNP do not correlate with interventioninduced changes in mortality. VO 2 and 6MW are legitimate and important therapeutic targets for patients with symptomatic HF because they represent measures of functional status for these patients. The natriuretic peptide BNP and the cleaved, inactive aminoterminal pro-BNP are frequently evaluated in research trials, and all of these intermediate markers have shown prognostic value for mortality in HF patients, when measured at one point in time. 9, 15, 121, 122 Along with measurements of LV dimensions and ejection fraction, these markers have recently been considered promising as surrogate markers for mortality in research trials of drug and device therapy on chronic HF. 7 It has been previously unknown how well intervention effects on these markers correlate with the effects of those same interventions on mortality.
The morbidity and mortality associated with HF result from a multifactorial and complex process, unlikely to be wholly captured by a single short-term marker. Furthermore, the specific mechanism of death differs among similar patients as previously documented in an analysis of the Vasodilator Heart Failure Trials (V-HeFT). 48 Previous authors have identified discrepancies between drug/ device effect on exercise tolerance and effect on overall survival. 7, 77, 123 This discrepancy is identified in the trial-level analysis of 6MW distance presented here and further suggests the limitations to using this functional marker as a surrogate for interventions effect on mortality. There are a number of reasons why therapeutic effects on the exercise outcomes of peak VO 2 and 6MW may not be predictive of therapy effect on mortality in patients with HF and LVD. It has been long appreciated that there is variability in peak VO 2 despite this outcome being considered "effort independent." 124 The failure of 6MW distance to directionally correlate with mortality is perhaps not surprising because it is often referred to as a subjective test, limited by patient effort and willingness to . Quantitative relationship between drug/device effects on 6-minute walk (6MW) distance and mortality: each data point represents a placebo-corrected change in 6MW distance from an individual trial plotted against the mortality odds ratio (OR) for the specific therapy. 8 Colorcoded mortality effect based on data from mortality trials is listed in online-only Supplement Table 1 . Interventions were classified as favorable (yellow circles) if the upper limit of the 95% confidence interval (CI) of the OR for death from the mortality trials was Ͻ1, neutral (red circles) if the 95% CI crossed 1. participate. Importantly, it has been previously demonstrated that patient performance varies significantly when patients are encouraged by those administering the test. 125 Additional reasons why intervention effect on exercise parameters does not correlate with effect on mortality include the relatively preserved exercise tolerance of the patients in these studies and that the markers themselves represent the interaction of numerous physiological parameters, such as cardiac output and reserve, the ability of skeletal muscle to extract oxygen from blood, and also pulmonary and endothelial function. 126 There is increasing evidence that exercise testing performs less well as a prognostic tool for patients with less severe HF and relatively preserved ability to exercise. 127 This is probably because of decreased event rates at higher levels of exercise tolerance. 10, 9 The final set of markers evaluated here, BNP and NT-proBNP, have relatively limited associated data in this analysis. This probably stems from the fact that natriuretic peptides are relatively new measures used in these HF clinical research trials. The first trials included in this analysis for these outcomes were published in 2000 (BNP) and 2004 (NT-proBNP). As a result of this recent arrival, there are relatively few published studies that follow changes in these natriuretic peptides through time during a placebo controlled intervention trial. Though these biomarkers have been shown to relate to prognosis and LV function in HF, there is limited information available to evaluate how well changes in these markers correlate with intervention effect on mortality. In fact, there are no data on drug or device effects on natriuretic peptides for interventions that have an unfavorable effect on mortality.
There are several important limitations to this study that deserve comment. Selection bias is a concern in any retrospective analysis. We attempted to minimize this bias by using a rigorous and systematic search strategy and also strict Figure 6 . Quantitative relationship between drug/device effects on brain natriuretic peptide (BNP) and mortality: Each data point represents a placebo-corrected change in BNP from an individual trial plotted against the mortality odds ratio (OR) for the specific therapy. 8 Colorcoded mortality effect based on data from mortality trials is listed in online-only Supplement Table 1 . Interventions were classified as favorable (yellow circles) if the upper limit of the 95% confidence interval (CI) of the OR for death from the mortality trials was Ͻ1, neutral (red circles) if the 95% CI crossed 1.
Figure 7.
Quantitative relationship between drug/device effects on N-terminal precursor protein brain natriuretic peptide (NT-proBNP) and mortality: Each data point represents a placebocorrected change in NT-proBNP from an individual trial plotted against the mortality odds ratio (OR) for the specific therapy. 8 Color-coded mortality effect based on data from mortality trials is listed in online-only Supplement Table 1 . Interventions were classified as favorable (yellow circles) if the upper limit of the 95% confidence interval (CI) of the OR for death from the mortality trials was Ͻ1, neutral (red circles) if the 95% CI crossed 1. a priori inclusion and exclusion criteria. An additional source of selection bias comes from the progression to large phase III mortality studies. If interventions with favorable effects on the short-term markers are selected for evaluation in larger mortality trials, an inflated number of therapies that have a positive effect on the proposed markers are evaluated in this analysis. Theoretically, this could bias toward the null. Equally as important, publication bias may affect our results. We were limited to published manuscripts, the majority of which were published before mandatory registration of research trials. The extent to which publication bias affects these results is unknown and is difficult to quantify. 128 An additional concern is that we grouped results from trials spanning different therapeutic eras involving a wide range of follow-up durations. External validation is not yet available for these results that represent the current published literature.
Most importantly, our analysis is sensitive to confounding and to ecological fallacy. Specifically, our data on short-term markers and on mortality come from independent sources (from different studies), and thus confounding by study is an important concern. Second, we studied associations between average changes in short-term outcomes and summary ORs for mortality; ideally we would evaluate these relationships using longitudinal individual patient data. The concept of ecological fallacy refers to the idea that relationships between averages can be misleading. This is particularly important when changes in markers are nonlinearly or nonmonotonically related to the probability of mortality. However, despite this limitation, we believe that this analysis generates hypotheses that can subsequently be tested using longitudinal data.
Conclusion
This analysis, limited to trial level data from different therapeutic eras, suggests that drug-or device-induced average effects on the functional markers of peak VO 2 , 6MW, and the biomarkers BNP and NT-proBNP do not predict therapeutic effects on mortality for patients with HF and reduced EF. Although these markers may objectively reflect functional capacity and may represent pathophysiological changes that are seen in HF, our findings do not provide support for their use as surrogates for an intervention's effect on long-term mortality. Continued work is needed to validate potential markers and find novel surrogates for research trials of therapies in HF. 
